Skip to main content
OpenTrials
Completed

NCT Number: NCT04219059

MR Radiomic Features in Prostate Cancer

A combination of correct interpretation of imaging and biopsy has given promising results in terms of detecting clinically significant cancer at radical prostatectomy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Prostate Cancer Genital Diseases Genital Diseases, Male Genital Neoplasms, Male Male Urogenital Diseases Neoplasms Neoplasms by Site Prostatic Diseases Prostatic Neoplasms Urogenital Diseases Urogenital Neoplasms

Age range

18 year and older

Sex eligibility

Male

Study type

Observational

Primary location

IRCCS Ospedale San Raffaele

Milan, 20153, Italy

About this study

Quantitative approaches to medical image analysis have been developed in recent years with the aim to overcome the limitation of qualitative image interpretation, and provide biomarkers for disease characterization. In particular, the new paradigm, "radiomics", is emerging as the high-throughput extraction of quantitative features from imaging which can aid in characterizing phenotype as in vivo expression of tumoral genotype. The goal of radiomics is to extract accurate and reliable quantitative biomarkers which enhance diagnostic confidence in oncology. A combination of correct interpretation of imaging and biopsy has given promising results in terms of detecting clinically significant cancer at radical prostatectomy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • > 18 years of age
  • In house MRI with contrast medium
  • PCa (prostate cancer) biopsy proven diagnosis
  • In house radical prostatectomy

Exclusion criteria

  • < 18 years of age
  • MRI without contrast medium
  • Radical prostatectomy executed not in Institution

Treatment and study plan

Primary outcomes

  1. Number of surrogate bioimaging markers of histological characteristics in MR images

    Time frame: 0-2 years

    Segment tumor volumes on the ADC map and extract different imaging features

Secondary outcomes

  1. Radiomic features from MRI

    Time frame: 0-2 years

    Evaluate if radiomic features on primitive prostate lesions can describe lymph node involvement.

  2. Extract radiomic features

    Time frame: 0-2 years

    Evaluate if radiomic features fro MRIon primitive prostate lesions can describe disease extension.

Sponsors and collaborators

Lead sponsor

IRCCS San Raffaele

Other

Collaborators

  • IBFM-CNR (Istituto di Bioimmagini e Fisiologia Molecolare, National Research Council, Segrate, Italy

Registry information

Important dates

Study start
2019
Primary completion
2021
Study completion
2021
First posted
Jan 6, 2020
Registry last updated
Jan 26, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.